Top Health Issues of 2019: A Report by PwC

December 13, 2018

PricewaterhouseCoopers’ (PwC) Health Research Institute (HRI) just released its flagship report, Top Health Industry Issues of 2019. In its 13^th year, this report highlights the trends PwC expects to most powerfully impact the US health industry in the coming year.

It’s no surprise that the US health industry has lagged behind other industries when it comes to modernizing. Once thought to operate outside the greater US economy, the health industry – with its byzantine payment system, complicated regulatory barriers and reliance on face-to-face interactions – is being disrupted. Finally, we see robust evidence that what we call the New Health Economy is kicking into gear.

Here are the trends we named to our list of top issues for 2019:

1. Digital therapeutics and connected care reshape the life sciences industry
2. Your company’s new, upskilled health worker of the future is you
3. Tax reform has only just begun for healthcare companies
4. Creating the Southwest Airlines of healthcare
5. Private equity: Healthcare’s new growth accelerator
6. The Affordable Care Act in 2019: Still alive

Our Top health industry issues report evaluates health organizations’ opportunities and obstacles for the new year, and can be used as you contemplate and develop business strategies for 2019.  To download the full report, visit Top health industry issues of 2019

Please contact Don Hulet at 801-537-5260 or donald.l.hulet@pwc.com  if you would like to discuss the report and schedule a private briefing with our Health Research Institute team. Also please consider attending our webinar on Jan. 16 at 1 pm EST (to register, please click here).

PwC’s HRI provides new intelligence, perspectives and analysis on trends affecting all health-related industries. HRI helps executive decision-makers navigate change through primary research and collaborative exchange. Our views are shaped by a network of professionals with executive and day-to-day experience in the health industry.

PwC’s Pharmaceutical and Life Sciences Industry Group is dedicated to delivering effective solutions to the complex strategic, operational and financial challenges facing pharmaceutical, biotechnology and medical devices companies. We provide industry-focused assurance, tax and advisory services to build public trust and enhance value for our clients and their stakeholders. More than 250,000 people in 158 countries across the PwC global network of firms share their thinking, experience, and solutions to develop fresh perspectives and practical advice. Visit us at www.pwc.com/us/pharma.